WA-AWS
26.5.2020 09:02:08 CEST | Business Wire | Press release
Today, Amazon Web Services (AWS), an Amazon.com company (NASDAQ: AMZN), and the German Bundesliga will debut the first two Bundesliga Match Facts powered by AWS during tonight’s highlight match at 18:30 CET featuring Borussia Dortmund vs. Bayern Muenchen on broadcast television in over 200 countries. The two new statistics, Average Positions and Expected Goals (xGoals), will give fans deeper insights into a team’s intended playing style based on real-time analysis performed of data captured from tracking players’ locations on the field, and the probability of a player scoring a goal. Germany’s top national football league will leverage AWS’s unmatched set of cloud services, including machine learning and analytics, to introduce additional advanced statistics in 2020 and upcoming seasons. AWS and the Bundesliga are the first to deliver this unique combination of real-time advanced statistics and game analyses to football (soccer) fans around the world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200526005205/en/
Bundesliga Match Facts are generated by gathering data from the live game video feeds that are streamed into AWS for analysis, and then provided back to broadcast viewers around the world in real-time as statistics. These statistics help audiences better understand things like the strategy involved in decision-making on the pitch and the probability of a goal for each shot. As of May 26, Average Positions will be available during future broadcasts of Bundesliga matches, while xGoals will be available during highlight matches.
A look at the two new Bundesliga Match Facts powered by AWS
Average Positions: Fans will now be able to see the positioning of a team’s players on the pitch and gain insight into the team’s intended playing style. Average Positions provides new insights based on analysis performed on data captured from tracking a player’s average location on the field, which is then displayed in real-time. This Bundesliga Match Fact allows viewers to identify the current momentum on the field and understand tactical changes. The new statistic will help pinpoint if a team is setting up in an attacking or defending style, pressing up the middle, or utilizing the wings. By displaying the average location and position of each player in real-time, Average Positions helps fans understand tactical changes as the game progresses.
xGoals : Using Amazon SageMaker, a fully managed service to build, train and deploy machine learning models, the Bundesliga can now assess the probability of a player scoring a goal when shooting from any position on the field. The goal probability is calculated in real-time for every shot to give viewers insight into the difficulty of a shot and the likelihood of a goal. To calculate the precision of xGoals, machine learning models were trained by analyzing 40,000 historical shots on goal in addition to an array of features derived from positional data, including distance to goal, angle to goal, player speed, number of defenders in line of shot, and goalkeeper coverage.
“We at Bundesliga are able to use this advanced technology from AWS, including statistics, analytics and machine learning, to interpret the data and deliver more in-depth insight and better understanding of the split-second decisions made on the pitch," said Andreas Heyden, Executive Vice President of Digital Innovations for the DFL Group. "The use of Bundesliga Match Facts enables viewers to gain a deeper insight into the key decisions in each match."
“AWS is helping the Bundesliga enhance the broadcast viewing experience by delivering deeper insights into the game that didn’t previously exist,” said Andy Isherwood, Vice President and Managing Director EMEA, AWS. “With AWS, Bundesliga is able to provide real-time statistics to predict future plays and outcomes. These two new statistics are just the beginning of what we’ll be able to deliver for football fans as we look forward to unlocking new ways to better educate, engage, and entertain viewers around the world.”
Football fans can follow all of the latest Bundesliga action, with Match Facts powered by AWS, on Bundesliga.com and via the official Facebook , Twitter , and Instagram channels.
About Amazon Web Services
For 14 years, Amazon Web Services has been the world’s most comprehensive and broadly adopted cloud platform. AWS offers over 175 fully featured services for compute, storage, databases, networking, analytics, robotics, machine learning and artificial intelligence (AI), Internet of Things (IoT), mobile, security, hybrid, virtual and augmented reality (VR and AR), media, and application development, deployment, and management from 76 Availability Zones (AZs) within 24 geographic regions, with announced plans for nine more Availability Zones and three more AWS Regions in Indonesia, Japan, and Spain. Millions of customers—including the fastest-growing startups, largest enterprises, and leading government agencies—trust AWS to power their infrastructure, become more agile, and lower costs. To learn more about AWS, visit aws.amazon.com .
About Amazon
Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. Customer reviews, 1-Click shopping, personalized recommendations, Prime, Fulfillment by Amazon, AWS, Kindle Direct Publishing, Kindle, Fire tablets, Fire TV, Amazon Echo, and Alexa are some of the products and services pioneered by Amazon. For more information, visit amazon.com/about and follow @AmazonNews .
About the Bundesliga
The Bundesliga is the top professional association football league in Germany. The league was established in 1963 and comprises 18 teams which operate on a system of promotion and relegation with the Bundesliga 2. The Bundesliga is broadcast on television in over 200 countries and is operated by the DFL Deutsche Fußball Liga.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200526005205/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Consortium Led by Axelspace Selected for Japan’s Space Strategy Fund Project “Technology to Enhance Capability of Next Generation Earth Observation Satellites”30.3.2026 01:35:00 CEST | Press release
~ Creating Climate Solutions and New Market Opportunities through Source-Specific CO2 Emission and Uptake Monitoring via Satellite Constellation and Aircraft ~ Axelspace Corporation, Meisei Electric Co., Ltd., ANA HOLDINGS INC., and JIJ Inc. are pleased to announce that their jointly proposed technology development project has been selected for Japan Aerospace Exploration Agency (JAXA)’s Space Strategy Fund under the theme “Technology to Enhance Capability of Next Generation Earth Observation Satellites.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323044518/en/ Conceptual Diagram of the project. Under this Space Strategy Fund initiative, spectrometers will be newly developed and demonstrated in orbit. In the future, the project envisions the establishment of a satellite constellation capable of observations at different times of the day. Project Summary (Planned) Technology Development Theme: Technology to Enhance Cap
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom